The biggest names in diabetes tech gathered in New Orleans last weekend for the American Diabetes Association’s 86th Scientific Sessions (ADA 2026). Clinical findings supporting next-generation automated insulin delivery platforms, continuous glucose monitors (CGMs) and all kinds of other technologies were on display in New Orleans. BTIG analysts Marie Thibault, Alexandra Pang and Sam Eiber […]
ADA 2026
Beta Bionics real-world data shows 25% time in range improvement with iLet
Beta Bionics (Nasdaq:BBNX) said real-world data discussed last weekend highlighted the impact of its iLet Bionic Pancreas platform. The company said conversations with clinicians at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans covered improved outcomes and easier follow-up visits. The Irvine, California-based company said outcomes demonstrated how iLet supports diabetes care […]
Sequel Med Tech chief medical officer explains why company is ‘excited about what’s ahead’
Sequel Med Tech has a habit of making waves at the American Diabetes Association’s annual Scientific Sessions event. In 2024, the Manchester, New Hampshire-based company was generating buzz following its entry into the automated insulin delivery market with twiist, its pump system, which had garnered FDA clearance in March of that year. At last year’s […]
Dexcom CEO Jake Leach talks Nutrisense acquisition, type 2 push, next-gen G8
Nearly halfway through 2026, the milestones are already stacking up for continuous glucose monitor (CGM) maker Dexcom (Nadsaq:DXCM). President and CEO Jake Leach took over the corner office in January. In the months that have followed, highlights include the unveiling of the next-generation G8 sensor system, the launch of the Flex sensor platform outside the […]
Biolinq data backs autonomous, needle-free CGM
Biolinq today shared new clinical findings supporting the use of its autonomous, needle-free continuous glucose monitor (CGM). San Diego-based Biolinq develops the Shine sensor, which integrates glucose, activity and sleep information into a single device with autonomous operation. The first-of-its-kind system utilizes a patch on the forearm to provide real-time glucose feedback through a primary […]
Terrestrial Bio data backs needle-free patch for GLP-1 delivery
Terrestrial Bio today shared new preclinical data demonstrating the translatability of its patch technology for delivering GLP-1 therapies. Boston-based Terrestrial (formerly Vaxess Technologies) shared findings at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. Outcomes showed the translatability of the proprietary Tacterra MAP platform to deliver next-generation obesity therapies that involve co-delivery […]
Sequel Med Tech data supports twiist automated insulin delivery in type 2 diabetes
Sequel Med Tech today announced clinical findings supporting its twiist automated insulin delivery (AID) system in type 2 diabetes. twiist, which works with the twiist Loop algorithm, powered by Tidepool, directly measures the volume of insulin delivered with every microdose. The system offers the capability and flexibility to address each patient’s individual dosing needs. Sequel’s system […]
Adaptyx study backs wearable multi-analyte sensor
Adaptyx Biosciences today announced clinical findings supporting its wearable sensor for continuous, multi-day free cortisol measurement. Menlo Park, California-based Adaptyx, a Stanford University spinout, shared the first data for its sensor at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. The studies looked at the sensor measuring free cortisol from dermal interstitial […]
Senseonics study supports Eversense 365 CGM with automated insulin delivery tech
Senseonics (NYSE:SENS) today announced real-world evidence supporting the performance of its Eversense 365 year-long CGM implant. Eversense 365 is a 365-day implantable continuous glucose monitor (CGM) that rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. Germantown, Maryland-based Senseonics said data […]
Dexcom study highlights benefits of G7 CGM in non-insulin type 2 diabetes
Dexcom (Nasdaq:DXCM) today announced findings from a study demonstrating the benefits of its G7 CGM in type 2 diabetes. The CONNECT study evaluated the current-generation G7 continuous glucose monitor (CGM) in people with type 2 diabetes not using insulin. It compared this population to a routine care control group using self-monitoring of blood glucose. Researchers shared […]
